Beijing Succeeder Technology Inc (688338) - Net Assets
Based on the latest financial reports, Beijing Succeeder Technology Inc (688338) has net assets worth CN¥1.71 Billion CNY (≈ $250.08 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.78 Billion ≈ $260.19 Million USD) and total liabilities (CN¥69.11 Million ≈ $10.11 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Beijing Succeeder Technology Inc (688338) strategic asset index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.71 Billion |
| % of Total Assets | 96.11% |
| Annual Growth Rate | 36.33% |
| 5-Year Change | 18.92% |
| 10-Year Change | N/A |
| Growth Volatility | 79.81 |
Beijing Succeeder Technology Inc - Net Assets Trend (2016–2025)
This chart illustrates how Beijing Succeeder Technology Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see 688338 stock market capitalisation.
Annual Net Assets for Beijing Succeeder Technology Inc (2016–2025)
The table below shows the annual net assets of Beijing Succeeder Technology Inc from 2016 to 2025. Also explore Beijing Succeeder Technology Inc net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.69 Billion ≈ $247.25 Million |
+2.64% |
| 2024-12-31 | CN¥1.65 Billion ≈ $240.89 Million |
+2.87% |
| 2023-12-31 | CN¥1.60 Billion ≈ $234.16 Million |
+6.36% |
| 2022-12-31 | CN¥1.50 Billion ≈ $220.16 Million |
+5.89% |
| 2021-12-31 | CN¥1.42 Billion ≈ $207.92 Million |
+4.77% |
| 2020-12-31 | CN¥1.36 Billion ≈ $198.45 Million |
+261.94% |
| 2019-12-31 | CN¥374.69 Million ≈ $54.83 Million |
+91.51% |
| 2018-12-31 | CN¥195.65 Million ≈ $28.63 Million |
+36.54% |
| 2017-12-31 | CN¥143.30 Million ≈ $20.97 Million |
+37.94% |
| 2016-12-31 | CN¥103.89 Million ≈ $15.20 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Beijing Succeeder Technology Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1953.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥570.37 Million | 33.75% |
| Other Components | CN¥1.12 Billion | 66.25% |
| Total Equity | CN¥1.69 Billion | 100.00% |
Beijing Succeeder Technology Inc Competitors by Market Cap
The table below lists competitors of Beijing Succeeder Technology Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Greenlight Capital Re Ltd
NASDAQ:GLRE
|
$500.15 Million |
|
Zhanjiang Guolian Aquatic Products
SHE:300094
|
$500.21 Million |
|
Autolus Therapeutics Ltd
NASDAQ:AUTL
|
$500.39 Million |
|
GREENLIGHT CAP.RE A DL-01
F:G8L
|
$500.81 Million |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
$500.03 Million |
|
LUBAWA SA
WAR:LBW
|
$500.00 Million |
|
Ginkgo Bioworks Holdings
NYSE:DNA
|
$499.99 Million |
|
Jiangsu Changqing Agrochemical Co Ltd
SHE:002391
|
$499.99 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Beijing Succeeder Technology Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,646,270,295 to 1,689,836,702, a change of 43,566,407 (2.6%).
- Net income of 87,143,189 contributed positively to equity growth.
- Dividend payments of 34,310,082 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥87.14 Million | +5.16% |
| Dividends Paid | CN¥34.31 Million | -2.03% |
| Other Changes | CN¥-9.27 Million | -0.55% |
| Total Change | CN¥- | 2.65% |
Book Value vs Market Value Analysis
This analysis compares Beijing Succeeder Technology Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.98x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 21.93x to 1.98x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | CN¥1.47 | CN¥32.20 | x |
| 2017-12-31 | CN¥1.95 | CN¥32.20 | x |
| 2018-12-31 | CN¥2.65 | CN¥32.20 | x |
| 2019-12-31 | CN¥3.53 | CN¥32.20 | x |
| 2020-12-31 | CN¥12.78 | CN¥32.20 | x |
| 2021-12-31 | CN¥13.39 | CN¥32.20 | x |
| 2022-12-31 | CN¥14.23 | CN¥32.20 | x |
| 2023-12-31 | CN¥15.08 | CN¥32.20 | x |
| 2024-12-31 | CN¥15.59 | CN¥32.20 | x |
| 2025-12-31 | CN¥16.25 | CN¥32.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Beijing Succeeder Technology Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.16%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 33.05%
- • Asset Turnover: 0.15x
- • Equity Multiplier: 1.04x
- Recent ROE (5.16%) is below the historical average (13.65%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 29.86% | 24.74% | 0.81x | 1.49x | CN¥20.63 Million |
| 2017 | 20.48% | 18.73% | 0.84x | 1.30x | CN¥15.02 Million |
| 2018 | 28.99% | 28.34% | 0.82x | 1.24x | CN¥37.15 Million |
| 2019 | 18.96% | 30.95% | 0.54x | 1.14x | CN¥33.57 Million |
| 2020 | 5.10% | 31.11% | 0.16x | 1.03x | CN¥-66.43 Million |
| 2021 | 6.85% | 40.58% | 0.16x | 1.04x | CN¥-44.72 Million |
| 2022 | 6.92% | 45.50% | 0.14x | 1.07x | CN¥-46.34 Million |
| 2023 | 7.31% | 42.44% | 0.16x | 1.07x | CN¥-43.11 Million |
| 2024 | 6.86% | 36.94% | 0.17x | 1.06x | CN¥-51.63 Million |
| 2025 | 5.16% | 33.05% | 0.15x | 1.04x | CN¥-81.84 Million |
Industry Comparison
This section compares Beijing Succeeder Technology Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $3,326,899,819
- Average return on equity (ROE) among peers: 19.90%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Beijing Succeeder Technology Inc (688338) | CN¥1.71 Billion | 29.86% | 0.04x | $500.13 Million |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $2.43 Billion | 8.55% | 0.44x | $465.89 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $11.92 Billion | 20.11% | 0.34x | $3.90 Billion |
| Double Medical Technology Inc (002901) | $3.18 Billion | 11.21% | 0.39x | $2.46 Billion |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $49.59 Million | 43.44% | 0.23x | $525.69 Million |
| Lepu Medical Tech Beijing (300003) | $10.54 Billion | 17.10% | 0.73x | $3.13 Billion |
| INKON Life Technology Co Ltd (300143) | $2.62 Billion | 2.62% | 0.60x | $854.32 Million |
| Edan Instruments Inc (300206) | $1.85 Billion | 12.58% | 0.21x | $992.43 Million |
| Guangdong Biolight Meditech Co Ltd (300246) | $585.84 Million | 11.05% | 0.64x | $623.76 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $83.90 Million | 31.18% | 0.36x | $479.23 Million |
| Sinocare Inc (300298) | $17.42 Million | 41.15% | 0.68x | $1.34 Billion |
About Beijing Succeeder Technology Inc
Beijing Succeeder Technology Inc. engages in the research, development, production, and sales of testing instruments, reagents, and consumables in the field of in vitro diagnostics for thrombosis and hemostasis in China and internationally. The company offers coagulation testers, hemorheology testers, erythrocyte sedimentation rate and hematocrit testers, platelet aggregation testers, blood rheol… Read more